Digest Network Come funziona
Network
/
Società
Ab
Non verificato

Abdera Therapeutics Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

5 comunicati stampa

Guarda tutti i comunicati
09/09/2025
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Medicina nucleare
Farmaceutica
Salute
Oncologia
Eventi
Industria
Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer
Fonte
Abdera Therapeutics Inc.
Emittente
Business Wire
1.00
0
08/07/2025
Sanità
Scienza
Medicina nucleare
Farmaceutica
Oncologia
Medicina - Varie
Biotecnologia
Igiene alimentare
Salute
Mercato del lavoro
Abdera Therapeutics Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Fonte
Abdera Therapeutics Inc.
Emittente
Business Wire
1.00
0
23/04/2025
Industria
Eventi
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Abdera Therapeutics to Present Key Updates on its Radiopharmaceutical Development Pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Fonte
Abdera Therapeutics Inc.
Emittente
Business Wire
1.00
0
09/01/2025
Eventi
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Abdera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Fonte
Abdera Therapeutics Inc.
Emittente
Business Wire
1.00
0
27/06/2024
Industria
Oncologia
Salute
Igiene alimentare
Medicina nucleare
Medicina - Varie
Farmaceutica
Biotecnologia
Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer
Fonte
Abdera Therapeutics Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0